Alzheimer Biomarker-Based Diagnostic Market Set to Reach $20.8B by 2035, Led by Quanterix, Fujirebio, C2N, Lantheus, Sysmex, Quest Diagnostics, and Siemens Healthineers.

The Alzheimer biomarker-based diagnostic market is driven by leading companies such as Quanterix, Fujirebio Diagnostics, C2N Diagnostics, Lantheus Holdings, Sysmex Corporation, Quest Diagnostics, and Siemens Healthineers. The market is expected to grow due to the increasing prevalence of Alzheimer's disease and the development of advanced diagnostic solutions, including blood-based biomarkers and imaging techniques.